Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET

Company Participants

Matt Calistri - Vice President of Corporate Strategy and Investor Relations

Anthony Coles - Chairperson and Chief Executive Officer

Raymond Sanchez - Chief Medical Officer

John Renger - Chief Scientific Officer

Mark Bodenrader - Interim Chief Financial Officer

Abraham Ceesay - President

Conference Call Participants

Umer Raffat - Evercore

Michael Yee - Jefferies

Paul Matteis - Stifel

Tazeen Ahmad - Bank of America

Max Skor - Morgan Stanley

Mohit Bansal - Wells Fargo

Rob Palermo - Goldman Sachs

Charles Duncan - Cantor Fitzgerad

Douglas Tsao - H.C. Wainwright

Operator

Good morning, and welcome to the Cerevel Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Investor Relations. Please go ahead.

Matt Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our third quarter 2022 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer. A. Ceesay, our President, will join us for Q&A.

During our call today, please refer to our press release from this morning, detailing our Q3 2022 performance as well as our updated corporate presentation, both of which are available on our website. I would remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the form and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties.

I will now hand the call over to Dr. Tony Coles, Chairperson and CEO of Cerevel to provide an overview of our achievements and outlook.

Anthony Coles

Thanks, Matt, and good morning, everyone. Thanks for joining us for our third quarter 2022 business results call. At Cerevel, we know our aspiration is to become the premier neuroscience company. Our recent financing of $599 million puts us in a strong position and now with more than $1 billion of capital on our balance sheet to fuel our pipeline.